Executive Director/Vice President – Medical Lead
Crescent Biopharma
Executive Director/Vice President – Medical Lead
Crescent Biopharma
Clinical-stage biotech developing solid-tumor therapies
Salary Range: 330000 to 365000 (Currency: USD) (Pay period: per-year-salary)
Clinical-stage biotech developing solid-tumor therapies
Crescent Biopharma develops oncology therapies for solid tumors, led by CR-001, a tetravalent bispecific antibody that blocks PD-1 and VEGF to boost anti-tumor immunity while inhibiting tumor blood vessel growth. CR-001 sits in a global Phase 1/2 ASCEND trial, and the pipeline also includes CR-002, an anti-PD-L1 antibody-drug conjugate, and CR-003, an ITGB6-targeted ADC. The company differentiates itself by combining immune checkpoint blockade with VEGF inhibition and other targeted modalities to build an immuno-oncology backbone for solid tumors, supported by strategic partnerships and substantial private placements. Crescent’s goal is to advance multi-agent regimens toward regulatory approval and commercial development for patients with solid tumors.
Explore more opportunities at Crescent Biopharma